The drug "Baraklyud": instructions for use, description, composition and reviews

"Baraklid" refers to antiretroviral drugs, is part of the group of nucleoside analogues. It is prescribed for the treatment of chronic HBV infections. The active component of the entecavir drug promptly suppresses the replication of hepatitis viruses .

Before taking the drug must necessarily be studied annotation. What does the instruction for use indicate? "Baraklud" (Baraclud) - a drug that is designed to reverse the flow of fibrotic processes in patients with cirrhosis of the liver.

Structure of the preparation

The drug is produced in two dosage versions - 0.5 and 1 mg of the effective entecavir component, visually different in color (white or pink, respectively).

The composition of the drug also includes:

• Polysorbate;
• Magnesium stearate;
• Lactose monohydrate;
• Hypromellose;
• Povidone;
• Dye Opadry.

pharmachologic effect

The active component of entecavir, which is an analog of guanosine nucleoside, has a pronounced selective effect on the hepatitis B virus.

Entecavir is phosphorylated to active triphosphate with a half-life of about 15 hours, the intracellular content of which is associated with the concentration of entecavir outside the cell. At the same time, there is no tangible accumulation of the active substance in the body. The drug "Baraklyud", the instruction for its use demonstrates its high efficiency, suppresses the activity of polymerase of the virus, affecting simultaneously three factors:

• Synthesis of a positive strand of HBV DNA;
• Reverse transcription of the negative strand of pregenomic mRNA;
• Priming of the enzyme HBV.

Triphosphate does not belong to strong retarders of cellular DNA enzymes, even with a significant content does not affect mitochondrial DNA synthesis.

Effect of the drug

The active substance of the drug is able to be absorbed from the digestive system in a short time and reaches its maximum content 30-90 minutes after taking the tablet.

The proportional increase in the indices Cmax and AUC occurs with the subsequent use of 0.1-1 mg of the drug "Baraclud". Instructions for use indicate the achievement of a balance on the 6-10th day of a single dose of the drug per day. The use of fatty foods significantly complicates the process of absorption of entecavir, reducing the indices Cmax and AUC by 45% and 20%, respectively.

The drug is rapidly absorbed into the tissue and binds to plasma proteins by 13%. The active component of the preparation does not refer to substrates, inhibitors or enzyme inducers in the P450 system. It is able to accumulate in the body and be excreted through the renal system through glomerular filtration and tubular secretions.

Indications for use

The drug "Baraklyud" is recommended for taking in the complex treatment of hepatitis B:

• With the symptoms of the current viral reduplication and an increase in the degree of transaminase activity in the serum, in the presence of histological manifestations of the current inflammation of the liver.
• Unrecovered liver lesions.

Significant relief of symptoms of liver disease occurs after taking the drug "Baraklyud." Tablets instructions for use recommend taking patients with chronic hepatitis B, complicated by the following liver diseases:

• Being in the stage of decompensation;
• Pathological conditions of the liver in the stage of compensation with established viral replication, diagnosed manifestations of liver fibrosis with increased AST and ALT.

Contraindications

The drug "Baraklyud" has the following contraindications:

• Increased susceptibility to entecavir and other substances that make up the drug;
• Hereditary lactose intolerance, glucose-galactose malabsorption, deficiency or absence of lactase enzyme in the body;
• Age is less than 18 years.

Persons with renal failure should take the drug as directed and under constant medical supervision.

Admission "Baraklyuda" during pregnancy is not recommended, with therapy it is necessary to stop breastfeeding.

Side effects

There may be various disorders of the digestive system during treatment with the drug "Baraklyud". The instructions for use clearly describe such side effects:

• indigestion;
• diarrhea;
• nausea and vomiting;
• dyspepsia.

Migraines, insomnia or drowsiness, decreased appetite and allergic reactions can also occur.

The use of the drug as a single therapeutic agent or in combination with other antiretroviral drugs can cause the appearance of severe hepatomegaly with steatosis, which can lead to the death of the patient.

In patients with a decompensated form of liver damage, lactacidosis can be observed, which is characterized by:

• General muscle weakness;
• Rapid breathing and the appearance of dyspnea;
• Nausea;
• A significant decrease in body weight;
• Pain in the peritoneum, epigastrium.

Also, taking the drug can cause other reactions of the body:

• Increased liver transaminases;
• Rashes on the skin;
• Anaphylactoid reactions.

In patients also suffering from decompensated liver lesions, in addition, such reactions of the organism were manifested:

• Kidney failure (in rare cases);
• High content of bilirubin in the blood;
• Decrease in the number of platelets to 50 thousand / mm ³ and below;
• Decrease in blood levels of bicarbonate;
• Increased ALT;
• More than threefold increase in lipase activity;
• Decreased albumin content.

"Baraklad" medication: route of administration and dose

The drug should be taken on an empty stomach, the time interval from the last meal before taking the drug should be more than two hours.

With compensated lesions of the liver, it is recommended to take "Baracluda" 0.5 mg daily. If resistance to lamivudine is detected, the dosage should be doubled.

Patients with unrecovered liver lesions prescribed 1 mg daily. For elderly patients and patients with renal insufficiency, the dose should be adjusted depending on the level of QC (creatinine concentration) in the blood.

Overdose

Information on cases of drug overdoses is not enough.

Volunteers on which clinical trials were conducted received a daily dose of 20 mg for a two-week period, or they were given a single, increased dose of 40 mg of Baraclud. The instruction for use asserts that no negative consequences have been identified.

Recommended postindromnoe treatment under the control of clinical manifestations.

Interaction with other drugs

Due to the fact that the active component of entecavir is excreted from the body mainly through the kidney system, complex therapy in combination with other drugs that directly or indirectly affect the functioning of the kidneys and affect tubular secretion can lead to an increase in the content of entecavir and active substances in the body Medicines.

Interactions of "Baracluda" with adenovirus, tenofovir, lamivudine were not recorded.

Precautionary measures

Taking a drug by patients who are not susceptible to lamivudine, leads to a risk of developing resistance.

There is also information about the emergence of exacerbations of hepatitis after the discontinuation of the drug "Baraklyud." Instructions for use describe the relief of such exacerbations without additional therapy.

special instructions

The admission of "Baracluda" both in the monotherapy and in complex treatment with other antiretroviral drugs, can lead to lactic acidosis, hepatomegaly accompanied by steatosis. At the same time, there is a risk of death.

The following categories of patients are at risk:

• Suffering from hepatomegaly;
• Subjects treated with nucleoside analogues;
• Having excessive body weight;
• Female patients.

The instruction on the use of the drug "Baraclud" notes the possibility of the formation of resistant strains of HIV. The active component of the drug entecavir is not recommended for the treatment of human immunodeficiency virus, since its effectiveness in this direction has not yet been fully explored.

In the treatment of patients with pathology of the renal system, an adjustment of the dose of the drug is necessary.

The safety and effectiveness of the use of "Baracluda" for the treatment of patients after liver transplantation are not known and require special precautions.

Storage conditions and costs

Storage and transportation of tablets should be carried out in a temperature range of 15-25 ° C. The drug is suitable for use for two years from the date of manufacture.

The drug is included in a special group of vital medicines, and therefore, certain categories of citizens are provided with a free grant of the drug "Baraklyud". Instruction for use fixes this fact.

The price of the drug in pharmacies in Moscow starts from 12 thousand rubles.

Patient's opinions

Indicates the high effectiveness of the drug "Baraklyud" instructions for use. The price, the testimonials of which testify to its democratic nature in comparison with the analogues of the drug, varies between 12-17 thousand per package, in which 30 tablets. This makes the drug quite popular and in demand among patients in the treatment of hepatitis B.

In negative reviews, the drug's side-effects and side effects, such as insomnia and nausea, are mostly mentioned.